Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS

Shunsuke Kitajima, Hajime Asahina, Ting Chen, Sujuan Guo, Laura Gutierrez Quiceno, Jillian D. Cavanaugh, Ashley A. Merlino, Shoichiro Tange, Hideki Terai, Jong Wook Kim, Xiaoen Wang, Shan Zhou, Man Xu, Stephen Wang, Zehua Zhu, Tran C. Thai, Chiaki Takahashi, Yujin Wang, Richard Neve, Susanna StinsonPablo Tamayo, Hideo Watanabe, Paul T. Kirschmeier, Kwok Kin Wong, David A. Barbie

研究成果: Article査読

20 被引用数 (Scopus)

抄録

Despite extensive efforts, oncogenic KRAS remains resistant to targeted therapy. Combined downstream RAL-TBK1 and MEK inhibition induces only transient lung tumor shrinkage in KRAS-driven genetically engineered mouse models (GEMMs). Using the sensitive KRAS;LKB1 (KL) mutant background, we identify YAP1 upregulation and a therapy-induced secretome as mediators of acquired resistance. This program is reversible, associated with H3K27 promoter acetylation, and suppressed by BET inhibition, resensitizing resistant KL cells to TBK1/MEK inhibition. Constitutive YAP1 signaling promotes intrinsic resistance in KRAS;TP53 (KP) mutant lung cancer. Intermittent treatment with the BET inhibitor JQ1 thus overcomes resistance to combined pathway inhibition in KL and KP GEMMs. Using potent and selective TBK1 and BET inhibitors we further develop an effective therapeutic strategy with potential translatability to the clinic. Kitajima et al. identify BET-regulated YAP1 upregulation as a mediator of acquired and intrinsic resistance in KRAS;LKB1 and KRAS;TP53 mutant lung cancer cells, respectively, to combined TBK1 and MEK inhibition and show that intermittent BET inhibition overcomes this resistance.

本文言語English
ページ(範囲)439-452.e6
ジャーナルCancer Cell
34
3
DOI
出版ステータスPublished - 2018 9 10
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 細胞生物学
  • 癌研究

フィンガープリント

「Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル